Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00766688 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 643
- Enrollment target
NCT00766688: Clinical Trial Phase 3 study, sponsored by Sanofi.
NCT00766688 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 643 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00766688, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 643 participants
- Enrollment target
Study Summary
The present study is assessing the efficacy and safety of AVE5530 (25 mg and 50 mg) in add-on to ongoing treatment with high doses of statin in a double-blind manner in comparison with placebo, in the management of patients with severe primary hypercholesterolemia considered as inadequately controlled despite their ongoing statin treatment. The main objective is to evaluate the effects of the association AVE5530+statin on LDL-C level reduction after 12 weeks of treatment. The effects of AVE5530 on other lipid parameters will be assessed as secondary objectives.
Interventions
- DRUG Placebo
- DRUG AVE5530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 643 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Why NCT00766688 stopped before completion
NCT00766688 is an interventional study that assigns participants to a tested intervention. The registered 643 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00766688 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00766688 about?
NCT00766688 is a clinical study titled "Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia". The present study is assessing the efficacy and safety of AVE5530 (25 mg and 50 mg) in add-on to ongoing treatment with high doses of statin in a double-blind manner in comparison with placebo, in the management of patients with severe primary hypercholesterolemia considered as inadequately controll...
What is the current status of trial NCT00766688?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 643 participants. The study started on 2008-10. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00766688?
The interventions under investigation include: Placebo (DRUG), AVE5530 (DRUG).
Who is sponsoring clinical trial NCT00766688?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00766688's enrollment target sits among peer trials
643 573rd of 2000 higher than 1,427 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05146297 · 644 participants · NA
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
- NCT06994442 · 644 participants · Phase 3
Optimizing Pain Treatment in Children On Mechanical Ventilation
- NCT05204888 · 642 participants · NA
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- NCT07012395 · 645 participants · Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia